{
  "blueprint_id": "Redunera",
  "ip_status": "Independent Moleculogic Design",
  "freedom_to_operate": {
    "QRX-3 overlap": "No protected formulation claims used",
    "compound usage": "Acetylcysteine, Pentoxifylline, Ubiquinone are off-patent",
    "novelty_elements": [
      "Histidine-Zn entropy buffer in renal-specific nanocarrier",
      "ROS-responsive hydrogel activation logic",
      "SEI-scored immune feedback dampening architecture"
    ],
    "legal_rationale": "Redunera diverges in composition, release mechanism, immune logic, and formulation path. QRX-3 served only as a reference class compound, not a source of invention."
  },
  "patent_strategy": {
    "filing_country_set": ["US", "EP", "JP", "CA", "AU"],
    "type": "Non-Provisional Utility",
    "provisional_filed": true,
    "planned_claims": [
      "Multi-layer release architecture for renal-targeted redox agents",
      "Entropy-based drug logic for CKD modulation",
      "Nanoformulated immunomodulatory co-delivery system"
    ]
  },
  "commercial_rights": {
    "owned_by": "Kunfirm Technologies",
    "licensable_as": "Standalone therapeutic or logic-enhancement module",
    "IP_conflict_with_Ebima": false
  },
  "sei_audit": {
    "audit_id": "SEI-IP-Redunera-2025-001",
    "ruling": "Unique therapeutic blueprint logic with no encroachment on QRX-3 protected claims",
    "confidence_level": "High"
  },
  "prepared_by": "Kunfirm Technologies | IP and SEI Governance Division",
  "prepared_date": "2025-06-30"
}
